cancer

Auto Added by WPeMatico

NEA-backed Personal Genome Diagnostics receives FDA clearance for its cancer diagnostic

Personal Genome Diagnostics, the venture-backed developer of a novel diagnostic kit for genomic profiling of different cancers in lab settings, has received clearance from the U.S. Food and Drug Administration for its PGDx elio tissue complete test.

The test’s approval is another step forward for precision therapies that rely on an understanding of the unique genomic profile of an individual patient’s tumor, according to the company.

The test detects single nucleotide variants and the small insertions and deletions known as indels. Single nucleotide variants, indels, and identifying characteristics like the tumor mutation burden can be used by physicians to determine how rapidly a disease like cancer to progress and can provide essential targets for precision therapies to individual tumors.

The information doctors collect from these tests can also be used to help oncologists identify patients for clinical trials.

The new diagnostics test cover 35 different tumor types.

“There has not, until this point, been one standardized test for all kinds of cancer that any lab across the country can perform,” said Dr. Pranil Chandra, Chief Medical Officer of Genomic and Clinical Pathology Services, PathGroup, an early collaborator for PGDx elio tissue complete, in a statement. “With this clearance, labs across the country will for the first time have an option for a regulated, standardized test that examines a broad view of cancer pathways and genomic signatures across advanced cancers.”

To date, Personal Genome Diagnostics has raised over $99 million, according to Crunchbase. The company’s investors include New Enterprise Associates, Bristol Myers Squibb, Inova Strategic Investments, Co-win Healthcare Fund, Helsinn Investment Fund, Windham Venture Partners, Maryland Venture Fund

“We are proud to have led the first institutional round for PGDx,” said Dr. Justin Klein, in a statement when the company raised a $75 million round back in 2018. “Rapid advances in immuno-oncology, targeted agents, and combination cancer therapies are heightening the importance of tumor genome testing that enables treatments to be targeted to those patients most likely to benefit.”

 

Judge blocks Texas from defunding Planned Parenthood

Authorities in Texas who falsely claimed that Planned Parenthood sells fetal body parts are prohibited from withholding federal Medicaid funds from Planned Parenthood, a federal judge ruled today. This is a significant legal victory for Planned Parenthood, which is under renewed conservative attack under President Donald Trump.

(more…)

Powered by WPeMatico

Despite Trump's vow to kill ACA, the American Cancer Society held annual fundraiser at Mar-a-Lago

Jonathan Peltz at the Miami New Times: “’Donald Trump’ and ‘protecting patients’ access to health care’ are two phrases that aren’t generally associated with each other. But that fact didn’t seem to bother the American Cancer Society (ACS), which hosted its fundraiser Rock Palm Beach at Trump’s Mar-a-Lago [on February 10].”

(more…)

Powered by WPeMatico

Using data science to beat cancer

Dividing cancer cell. Coloured scanning electron micrograph (SEM) of a colorectal cancer cell undergoing mitosis (nuclear division) and splitting into two daughter cells (left and right). Here, it is in late telophase, the final stage before cell division (cytokinesis) and the two daughter cells are still connect by a cytoplasmic bridge (horizontal, centre). Bacteria (rod-shaped) can also be seen on the cells. Magnification: x2000 when printed at 10 centimetres wide. Image: STEVE GSCHMEISSNER/Science Photo Library
/Getty Images The complexity of seeking a cure for cancer has vexed researchers for decades. While they’ve made remarkable progress, they are still waging a battle uphill as cancer remains one of the leading causes of death worldwide. Yet scientists may soon have a critical new ally at their sides — intelligent machines — that can attack that complexity in a different way. Read More

Powered by WPeMatico